Tag: acquisition

Mergers and Acquisitions

Chiesi expands rare disease portfolio with Amryt Pharma acquisition

January 9, 2023

Via: Pharmaphorum

Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 billion, with upfront consideration of $1.25 billion representing a 107% premium […]

Industry, Mergers and Acquisitions, Pharma

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

December 28, 2022

Via: Pharmaphorum

In pharma, multi-billion-dollar deals dominate M&A headlines, but most deals are far shorter of this range and generally lie between $10-$500 million. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma […]

Cell and Gene Therapy, Clinical Trials, Industry, Research and Development

Gilead buys into multiple myeloma cell therapy with Arcellx deal

December 9, 2022

Via: Biopharma Dive

Gilead placed a major bet on cell therapy with its $12 billion acquisition of Kite in 2017. To the frustration of some investors, the business took several years to ramp up. But sales have substantially grown in recent months. Gilead’s […]

Cell and Gene Therapy, Industry, Mergers and Acquisitions

AstraZeneca Acquires Neogene, Expanding in Cancer Cell Therapy

November 30, 2022

Via: GEN

AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the buyer’s portfolio of cancer-fighting cell therapies. Neogene specializes in discovering, developing, and manufacturing next-generation T-cell receptor […]

Mergers and Acquisitions

J&J to Acquire Momenta Pharmaceuticals for $6.5B

August 19, 2020

Via: Contract Pharma

Johnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in cash. This acquisition expands Janssen Pharmaceutical’s portfolio in immune-mediated diseases into autoantibody-driven disease. J&J gains global rights to nipocalimab (M281), a […]